A part of Watch Media

MedWatchFriday27 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
21/01/2022at 15:40

Top news from MedWatch this week

Miss anything?
Photo: MedWatch
by MIKKEL AABENHUS HEMMINGSEN

Monday

Novo Nordisk settles securities lawsuit in Denmark

Snipr Biome chose clinical debut in CRISPR-ready USA

Tuesday

Bioinnovation Institute ramps up ambitions, wants twice as many companies under its wing

Leo Pharma and Roche want to strengthen clinical research in Denmark

Wednesday

Layoffs and restructuring will prepare Leo Pharma for IPO

Bavarian Nordic brings in chief operating officer from GSK Vaccines

Sonova wins Veterans Affairs market shares in December

Novo Nordisk partners with Swiss biotech firm on obesity – zebrafish to unlock new drugs

GN enters partnership to detect cognitive impairment in people with hearing loss

Orphazyme upgrades after careful spending year

Thursday

Leo Pharma ends Boston bet

Overwhelming majority passes new EMA powers

Overwhelming majority passes new EMA powers

WSA merges with its independent retailer

Hearing aid industry association responds to FDA’s proposed OTC regulation

Friday

Hearing firms urge FDA to increase OTC safety requirements

Novo Nordisk launches oral semaglutide in India

Coloplast initiates trial of ostomy leakage product



Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Agc Biologics
Pharma & biotech

AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes

The contract manufacturer will produce Tzield, an approved treatment that delays the onset of stage 3 type 1 diabetes, for Provention Bio, which secured rights from Lilly’s partner in 2018.
  • AGC's Japanese and Danish factories to produce German biotech firm's drug candidate
  • AGC Biologics breaks ground on USD 190m Danish factory

For subscribers

Per Wold-Olsen will not seek re-election as GN Group's chair in March | Foto: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix
Hearing health

Per Wold-Olsen's retirement is "a great loss for GN"

For subscribers

Katrine Hammer (right), chief executive officer of Philips Medisize A/S in Denmark and vice president for global innovation and development in Europe | Foto: Phillips-medisize
Medtech

US medtech group expands production in Denmark

For subscribers

Per Wold-Olsen, outgoing chairman of GN's board | Foto: Mik Eskestad
Hearing health

GN's veteran chairman to retire

For subscribers

Jesper J. Lange, co-founder and CEO of MC2 Therapeutics | Foto: Mc2 Therapeutics / Pr
Pharma & biotech

MC2 Therapeutics CEO steps down as board member

For subscribers

Foto: Sebastian Kahnert/AP/Ritzau Scanpix
Pharma & biotech

Atrogi doses first patient in diabetes study

For subscribers

Further reading

Per Wold-Olsen will not seek re-election as GN Group's chair in March | Foto: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix
Hearing health

Per Wold-Olsen's retirement is "a great loss for GN"

An analyst reacts to the news that GN’s chair is not seeking re-election this year – ”he has been key in helping GN secure a significant position on the hearing aid market.”

For subscribers

Foto: Agc Biologics
Pharma & biotech

AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes

The contract manufacturer will produce Tzield, an approved treatment that delays the onset of stage 3 type 1 diabetes, for Provention Bio, which secured rights from Lilly’s partner in 2018.

For subscribers

Foto: Euha/foto Rechnitz
Hearing health

New batch of hearing firm recommendations moves GN up, Demant and Sonova down

Jefferies takes stock of hearing aid industry, and comes up with a new string of recommendations.

For subscribers

Latest news

  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
  • US medtech group expands production in Denmark – 26 Jan
  • GN's veteran chairman to retire – 26 Jan
  • MC2 Therapeutics CEO steps down as board member – 26 Jan
  • Atrogi doses first patient in diabetes study – 26 Jan
  • FDA approves ALK's house dust mite tablet for teens – 25 Jan
  • Bavarian Nordic featured on Cowen list of 2023 biotech favorites – 25 Jan
  • Biontech inks deal with UK on sped-up cancer trials – 25 Jan
  • FDA vaccine director flagged concerns over "hyper-accelerated" review of Pfizer's Covid-19 vaccine – 25 Jan
See all

Jobs

  • Lead Data Architect

  • Application Manager

  • Head of Regulatory Affairs Danmark

  • Commercial Director

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Senior Regulatory Affairs Professional

  • Application Manager

  • Clinical Operational Associate

  • Sr. Director, Drug Safety Physician

  • Principal Laboratory Technologist

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Head of International Sales

See all jobs

Jobs

  • Lead Data Architect

  • Application Manager

  • Head of Regulatory Affairs Danmark

  • Commercial Director

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Senior Regulatory Affairs Professional

  • Application Manager

  • Clinical Operational Associate

  • Sr. Director, Drug Safety Physician

  • Principal Laboratory Technologist

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Head of International Sales

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge